AcelRx Pharmaceuticals, Inc (ACRX)

Etorro trading 970x250
AcelRx Pharmaceuticals, Inc (ACRX) Logo

About AcelRx Pharmaceuticals, Inc

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company’s lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California. Address: 351 Galveston Drive, Redwood City, CA, United States, 94063

AcelRx Pharmaceuticals, Inc News and around…

Latest news about AcelRx Pharmaceuticals, Inc (ACRX) common stock and company :

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Provention Bio, Danimer Scientific, AcelRX, and Piedmont Lithium on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
22 Oct, 2021 Yahoo! Finance

NEW YORK, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors of Provention Bio, Inc. (NASDAQ: PRVB), Danimer Scientific, Inc. (NYSE: DNMR), AcelRX Pharmaceuticals, Inc. (NASDAQ: ACRX), and Piedmont Lithium Inc. (NASDAQ: PLL) on behalf of long-term stockholders. More information about each potential case can be found at the link provided. Provention Bio, Inc. (NASDAQ: PRVB) Bragar Eage

How Bad Are AcelRx Pharmaceuticals's Earnings? | Return On Capital Employed
04 Oct, 2021 FinancialContent

AcelRx Pharmaceuticals (NASDAQ:ACRX) brought in sales totaling $443.00 thousand during Q2 according to data provided by Benzinga Pro. ...

Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors
04 Oct, 2021 Yahoo! Finance

Appointment of New Director with Significant Experience in Drug Development, Licensing and CommercializationSAN DIEGO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the appointment of Meera J. Desai, Ph.D., as a new director and member of the company’s board of directors. Dr. Desai replaces Roshawn Blunt, who retired from the Board effective October 1, 2021. Richard Williams, Chairman of the Board, commented: “We are pleased to welcome Dr. De

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Long Term Investor Notice: Investigation of Potential Wrongdoing
29 Sep, 2021 FinancialContent

San Diego, CA -- (SBWIRE) -- 09/29/2021 -- Certain directors of AcelRx Pharmaceuticals, Inc. are under investigation concerning potential breaches of fiduciary duties.

AcelRx Pharmaceuticals to Participate in Two September Investor Conferences
10 Sep, 2021 Yahoo! Finance

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will be providing an overview of the business and company updates at the H.C. Wainwright & Co. 23rd Annual Global Investment Conference taking place September 13-15, 2021, and at the Cantor Fitzgerald Virtual Global Healthcare Conference taking place September 27

Lifshitz Law Firm, P.C. Announces Investigations of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Frequency Therapeutics, Inc. (NasdaqGS: FREQ), RLX Technology Inc. (NYSE: RLX), and Washington Prime Group, Inc. (NYSE: WPG)
30 Aug, 2021 Yahoo! Finance

NEW YORK, NY / ACCESSWIRE / August 30, 2021 / Lifshitz Law Firm, P. (NASDAQ:ACRX)Lifshitz Law Firm, P.

Study Results Announced During Award-Winning Presentation on the Effect of Sufentanil Sublingual Tablet on Outpatient Plastic Surgery at the Annual Miami Cosmetic Surgery Event
30 Aug, 2021 Yahoo! Finance

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the results of a study evaluating sufentanil sublingual tablet 30 mcg (SST) for outpatient plastic surgery that was presented during the Miami Cosmetic Surgery (MCS) conference on Friday, August 27th at the Miami Beach Convention Center in Miami Beach, Florida.

Presentation on the Effect of the Administration of Sufentanil Sublingual Tablet on Reducing Post-Operative Recovery Time and Opioid Use in Plastic Surgery at the Annual Miami Cosmetic Surgery Event
26 Aug, 2021 Yahoo! Finance

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced an upcoming presentation on the effects of administering sufentanil sublingual tablet 30 mcg (SST) at Miami Cosmetic Surgery held at the Miami Beach Convention Center in Miami Beach, Florida from August 25-27, 2021.

21 Stocks Moving in Thursday's Pre-Market Session
19 Aug, 2021 FinancialContent

Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares rose 86.5% to $1.39 in pre-market trading after dropping 12% ...

46 Biggest Movers From Yesterday
19 Aug, 2021 FinancialContent

Gainers PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares climbed 189.5% to close at $9.90 on Wednesday after surging over 15% on ...

5 Penny Stocks To Buy According To Top Wall Street Analysts In 2021
18 Aug, 2021 FinancialContent
12 Health Care Stocks Moving In Wednesday's Intraday Session
18 Aug, 2021 FinancialContent

Gainers PharmaCyte Biotech (NASDAQ:PMCB) shares rose 119.0% to $7.49 during Wednesday's regular session. Trading ...

34 Stocks Moving In Wednesday's Mid-Day Session
18 Aug, 2021 FinancialContent

Gainers PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares jumped 139% to $8.18 after surging over 15% on Tuesday. Virpax ...

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
18 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

22 Stocks Moving in Wednesday's Pre-Market Session
18 Aug, 2021 FinancialContent

Gainers Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares rose 50.6% to $23.12 in pre-market trading. Virpax Pharmaceuticals ...

12 Health Care Stocks Moving In Tuesday's Intraday Session
17 Aug, 2021 FinancialContent

Gainers Aerpio Pharmaceuticals (NASDAQ:ARPO) stock increased by 25.72% to $2.59 during Tuesday's regular session. ...

AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Lags Revenue Estimates
16 Aug, 2021 Yahoo! Finance

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0.00% and -19.46%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

AcelRx Pharmaceuticals: Q2 Earnings Insights
16 Aug, 2021 FinancialContent

Shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) fell 6.8% in after-market trading after the company reported Q2 results. Quarterly ...

AcelRx Pharmaceuticals Reports Second Quarter 2021 Financial Results
16 Aug, 2021 Yahoo! Finance

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its second quarter 2021 financial results.

Earnings Scheduled For August 16, 2021
16 Aug, 2021 FinancialContent

Companies Reporting Before The Bell • Entera Bio (NASDAQ:ENTX) is likely to report earnings for its second ...

Moore Kuehn, PLLC Encourages Investors of ACRX to Contact Law Firm
12 Aug, 2021 Yahoo! Finance

New York, New York--(Newsfile Corp. - August 12, 2021) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating potential claims involving directors and officers regarding possible breaches of fiduciary duties related to whether insiders caused their companies to make false and/or misleading statements and/or failed to disclose, among other things, that:AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)The company or its officers and directors made false and/or misleading sta

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AcelRx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ACRX
09 Aug, 2021 Yahoo! Finance

Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-04353, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired AcelRx securities between March 17, 2020 and February 12, 2021, both

ACRX Last Few Hours to Deadline: Shareholders With Losses Exceeding $50K in AcelRx Pharmaceuticals, Inc. Are Encouraged to Contact Bronstein, Gewirtz & Grossman, LLC
09 Aug, 2021 Yahoo! Finance

NEW YORK, NY / ACCESSWIRE / August 9, 2021 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ('AcelRx' or 'the Company') (NASDAQ:ACRX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired AcelRx securities between March 17, 2020 and February 12, 2021, (the 'Class Period').

DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
09 Aug, 2021 Yahoo! Finance

Los Angeles, California--(Newsfile Corp. - August 9, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AcelRx Pharmaceuticals, Inc. ("AcelRx" or "the Company") (NASDAQ: ACRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between March 17, 2020 and February 12

ACRX Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds AcelRx Pharmaceuticals, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: August 9, 2021
09 Aug, 2021 Yahoo! Finance

New York, New York--(Newsfile Corp. - August 9, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or "the Company") (NASDAQ: ACRX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired AcelRx securities between March 17, 2020 and February 12, 2021, (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's ...

ACRX Final Deadline Today: Rosen, Trusted National Trial Counsel, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important August 9 Deadline in Securities Class Action - ACRX
09 Aug, 2021 Yahoo! Finance

New York, New York--(Newsfile Corp. - August 9, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020 and February 12, 2021, inclusive (the "Class Period"), of the important August 9, 2021 lead plaintiff deadline.SO WHAT: If you purchased AcelRx securities during the Class Period you may be entitled to compensation without payment of any out of pocket ...

AcelRx to Host Second Quarter 2021 Financial Results Call and Webcast on August 16, 2021
09 Aug, 2021 Yahoo! Finance

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after market close on Monday, August 16, 2021. AcelRx management will host a live webcast and conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on August 16, 2021 to discuss the financial results and provide an update on the company's business.

LEAD PLAINTIFF DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
09 Aug, 2021 Yahoo! Finance

LOS ANGELES, CA / ACCESSWIRE / August 9, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AcelRx Pharmaceuticals, Inc. ('AcelRx' or 'the Company') (NASDAQ:ACRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.

ACRX Final Deadline Tomorrow: Shareholders With Losses Exceeding $50K in AcelRx Pharmaceuticals, Inc. Should Contact Bronstein, Gewirtz & Grossman, LLC
08 Aug, 2021 Yahoo! Finance

NEW YORK, NY / ACCESSWIRE / August 8, 2021 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ('AcelRx' or 'the Company') (NASDAQ:ACRX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired AcelRx securities between March 17, 2020 and February 12, 2021, (the 'Class Period').

ACRX FINAL DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Monday Deadline in Securities C
07 Aug, 2021 FinancialContent

AcelRx Pharmaceuticals, Inc (ACRX) is a NASDAQ Common Stock listed in , ,

970x250